Skip to main content
Erschienen in:

02.12.2021 | Original Article

Dapagliflozin Improves Cardiac Function, Remodeling, Myocardial Apoptosis, and Inflammatory Cytokines in Mice with Myocardial Infarction

verfasst von: Kai Wang, Zhongming Li, Yan Sun, Xianling Liu, Wenjie Ma, Yinzhang Ding, Jian Hong, Lijun Qian, Di Xu

Erschienen in: Journal of Cardiovascular Translational Research | Ausgabe 4/2022

Einloggen, um Zugang zu erhalten

Abstract

Dapagliflozin (DAPA) exerts cardioprotective effects in non-diabetic patients. Nonetheless, the protective mechanism remains unknown. This study aims to evaluate the performance of DAPA on cardiac function and remodeling as well as its potential mechanism in mice with myocardial infarction (MI). Here, a MI mice model was established. One week after MI, mice were treated with saline or DAPA (1.5 mg/kg/day) for 4 weeks. At the end of this study, echocardiography was performed to assess cardiac structure and function. Myocardial apoptosis was analyzed by Western blot and immunofluorescence. Inflammatory cytokines and cardiac fibrosis were analyzed by real-time PCR and Masson’s trichrome stain, respectively. Results showed that DAPA improved cardiac structure and function, attenuated cardiac fibrosis, and inhibited inflammatory cytokines and myocardial apoptosis. Moreover, the inhibition of PI3K/AKT/mTOR pathway might be related to the cardioprotective role of DAPA. These findings reveal that dapagliflozin is a potential therapeutic agent for MI patients without diabetes.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Liu, S., Du, Y., Shi, K., Yang, Y., & Yang, Z. (2019b). Resveratrol improves cardiac function by promoting M2-like polarization of macrophages in mice with myocardial infarction. Am J Transl Res, 11(8), 5212–5226. Liu, S., Du, Y., Shi, K., Yang, Y., & Yang, Z. (2019b). Resveratrol improves cardiac function by promoting M2-like polarization of macrophages in mice with myocardial infarction. Am J Transl Res, 11(8), 5212–5226.
2.
Zurück zum Zitat Weir, R. A., McMurray, J. J., & Velazquez, E. J. (2006). Epidemiology of heart failure and left ventricular systolic dysfunction after acute myocardial infarction: Prevalence, clinical characteristics, and prognostic importance. American Journal of Cardiology, 97(10a), 13f–25f.CrossRef Weir, R. A., McMurray, J. J., & Velazquez, E. J. (2006). Epidemiology of heart failure and left ventricular systolic dysfunction after acute myocardial infarction: Prevalence, clinical characteristics, and prognostic importance. American Journal of Cardiology, 97(10a), 13f–25f.CrossRef
3.
Zurück zum Zitat Kelly, D. J., Gershlick, T., Witzenbichler, B., Guagliumi, G., Fahy, M., Dangas, G., Mehran, R., & Stone, G. W. (2011). Incidence and predictors of heart failure following percutaneous coronary intervention in ST-segment elevation myocardial infarction: The HORIZONS-AMI trial. American Heart Journal, 162(4), 663–670.CrossRefPubMed Kelly, D. J., Gershlick, T., Witzenbichler, B., Guagliumi, G., Fahy, M., Dangas, G., Mehran, R., & Stone, G. W. (2011). Incidence and predictors of heart failure following percutaneous coronary intervention in ST-segment elevation myocardial infarction: The HORIZONS-AMI trial. American Heart Journal, 162(4), 663–670.CrossRefPubMed
4.
Zurück zum Zitat Bolognese, L., Neskovic, A. N., Parodi, G., Cerisano, G., Buonamici, P., Santoro, G. M., & Antoniucci, D. (2002). Left ventricular remodeling after primary coronary angioplasty: Patterns of left ventricular dilation and long-term prognostic implications. Circulation, 106(18), 2351–2357.CrossRefPubMed Bolognese, L., Neskovic, A. N., Parodi, G., Cerisano, G., Buonamici, P., Santoro, G. M., & Antoniucci, D. (2002). Left ventricular remodeling after primary coronary angioplasty: Patterns of left ventricular dilation and long-term prognostic implications. Circulation, 106(18), 2351–2357.CrossRefPubMed
5.
Zurück zum Zitat Margaritis, M., Sanna, F., Lazaros, G., Akoumianakis, I., Patel, S., Antonopoulos, A. S., Duke, C., Herdman, L., Psarros, C., Oikonomou, E. K., Shirodaria, C., Petrou, M., Sayeed, R., Krasopoulos, G., Lee, R., Tousoulis, D., Channon, K. M., & Antoniades, C. (2017). Predictive value of telomere length on outcome following acute myocardial infarction: Evidence for contrasting effects of vascular vs. blood oxidative stress. Eur Heart J, 38(41), 3094–3104. Margaritis, M., Sanna, F., Lazaros, G., Akoumianakis, I., Patel, S., Antonopoulos, A. S., Duke, C., Herdman, L., Psarros, C., Oikonomou, E. K., Shirodaria, C., Petrou, M., Sayeed, R., Krasopoulos, G., Lee, R., Tousoulis, D., Channon, K. M., & Antoniades, C. (2017). Predictive value of telomere length on outcome following acute myocardial infarction: Evidence for contrasting effects of vascular vs. blood oxidative stress. Eur Heart J, 38(41), 3094–3104.
6.
Zurück zum Zitat Wortmann, S. B., Van Hove, J. L. K., Derks, T. G. J., Chevalier, N., Knight, V., Koller, A., Oussoren, E., Mayr, J. A., van Spronsen, F. J., Lagler, F. B., Gaughan, S., Van Schaftingen, E., & Veiga-da-Cunha, M. (2020). Treating neutropenia and neutrophil dysfunction in glycogen storage disease type Ib with an SGLT2 inhibitor. Blood, 136(9), 1033–1043. Wortmann, S. B., Van Hove, J. L. K., Derks, T. G. J., Chevalier, N., Knight, V., Koller, A., Oussoren, E., Mayr, J. A., van Spronsen, F. J., Lagler, F. B., Gaughan, S., Van Schaftingen, E., & Veiga-da-Cunha, M. (2020). Treating neutropenia and neutrophil dysfunction in glycogen storage disease type Ib with an SGLT2 inhibitor. Blood, 136(9), 1033–1043.
7.
Zurück zum Zitat Akinci, B. (2019). Dapagliflozin and cardiovascular outcomes in type 2 diabetes. New England Journal of Medicine, 380(19), 1881. Akinci, B. (2019). Dapagliflozin and cardiovascular outcomes in type 2 diabetes. New England Journal of Medicine, 380(19), 1881.
8.
Zurück zum Zitat McMurray, J. J. V., Solomon, S. D., Inzucchi, S. E., Køber, L., Kosiborod, M. N., Martinez, F. A., Ponikowski, P., Sabatine, M. S., Anand, I. S., Bělohlávek, J., Böhm, M., Chiang, C. E., Chopra, V. K., de Boer, R. A., Desai, A. S., Diez, M., Drozdz, J., Dukát, A., Ge, J., & Langkilde, A. M. (2019). Dapagliflozin in patients with heart failure and reduced ejection fraction. New England Journal of Medicine, 381(21), 1995–2008. McMurray, J. J. V., Solomon, S. D., Inzucchi, S. E., Køber, L., Kosiborod, M. N., Martinez, F. A., Ponikowski, P., Sabatine, M. S., Anand, I. S., Bělohlávek, J., Böhm, M., Chiang, C. E., Chopra, V. K., de Boer, R. A., Desai, A. S., Diez, M., Drozdz, J., Dukát, A., Ge, J., & Langkilde, A. M. (2019). Dapagliflozin in patients with heart failure and reduced ejection fraction. New England Journal of Medicine, 381(21), 1995–2008.
9.
Zurück zum Zitat Li, C. Y., Zhang, J. R., Li, X. X., Zhao, L., Xi, H., Hu, W. N., & Li, S. N. (2021). Lefty1 ameliorates post-infarction fibrosis by suppressing p-Smad2 and p-ERK1/2 signaling pathways. Journal of Cardiovascular Translational Research. https://doi.org/10.1007/s12265-020-10089-2 Li, C. Y., Zhang, J. R., Li, X. X., Zhao, L., Xi, H., Hu, W. N., & Li, S. N. (2021). Lefty1 ameliorates post-infarction fibrosis by suppressing p-Smad2 and p-ERK1/2 signaling pathways. Journal of Cardiovascular Translational Research. https://​doi.​org/​10.​1007/​s12265-020-10089-2
10.
Zurück zum Zitat Arow, M., Waldman, M., Yadin, D., Nudelman, V., Shainberg, A., Abraham, N. G., Freimark, D., Kornowski, R., Aravot, D., Hochhauser, E., & Arad, M. (2020). Sodium-glucose cotransporter 2 inhibitor Dapagliflozin attenuates diabetic cardiomyopathy. Cardiovascular Diabetology, 19(1), 7. Arow, M., Waldman, M., Yadin, D., Nudelman, V., Shainberg, A., Abraham, N. G., Freimark, D., Kornowski, R., Aravot, D., Hochhauser, E., & Arad, M. (2020). Sodium-glucose cotransporter 2 inhibitor Dapagliflozin attenuates diabetic cardiomyopathy. Cardiovascular Diabetology, 19(1), 7.
11.
Zurück zum Zitat Kilkenny, C., Browne, W. J., Cuthill, I. C., Emerson, M., & Altman, D. G. (2012). Improving bioscience research reporting: The ARRIVE guidelines for reporting animal research. Osteoarthritis Cartilage, 20(4), 256–260.CrossRefPubMed Kilkenny, C., Browne, W. J., Cuthill, I. C., Emerson, M., & Altman, D. G. (2012). Improving bioscience research reporting: The ARRIVE guidelines for reporting animal research. Osteoarthritis Cartilage, 20(4), 256–260.CrossRefPubMed
12.
Zurück zum Zitat Lu, D., Wang, K., Wang, S., Zhang, B., Liu, Q., Zhang, Q., Geng, J., & Shan, Q. (2017). Beneficial effects of renal denervation on cardiac angiogenesis in rats with prolonged pressure overload. Acta Psychologica, 220(1), 47–57. Lu, D., Wang, K., Wang, S., Zhang, B., Liu, Q., Zhang, Q., Geng, J., & Shan, Q. (2017). Beneficial effects of renal denervation on cardiac angiogenesis in rats with prolonged pressure overload. Acta Psychologica, 220(1), 47–57.
13.
Zurück zum Zitat Li, C., Zhang, J., Xue, M., Li, X., Han, F., Liu, X., Xu, L., Lu, Y., Cheng, Y., Li, T., Yu, X., Sun, B., & Chen, L. (2019). SGLT2 inhibition with empagliflozin attenuates myocardial oxidative stress and fibrosis in diabetic mice heart. Cardiovascular Diabetology, 18(1), 15. Li, C., Zhang, J., Xue, M., Li, X., Han, F., Liu, X., Xu, L., Lu, Y., Cheng, Y., Li, T., Yu, X., Sun, B., & Chen, L. (2019). SGLT2 inhibition with empagliflozin attenuates myocardial oxidative stress and fibrosis in diabetic mice heart. Cardiovascular Diabetology, 18(1), 15.
14.
Zurück zum Zitat Lim, C., Xu, J. C., Chen, T. Y., Xu, J. X., Chen, W. F., Hu, J. W., Li, Q. L., & Zhang, Y. Q. (2020). Ubiquitin-specific peptide 22 acts as an oncogene in gastric cancer in a son of sevenless 1-dependent manner. Cancer Cell International, 20, 45. Lim, C., Xu, J. C., Chen, T. Y., Xu, J. X., Chen, W. F., Hu, J. W., Li, Q. L., & Zhang, Y. Q. (2020). Ubiquitin-specific peptide 22 acts as an oncogene in gastric cancer in a son of sevenless 1-dependent manner. Cancer Cell International, 20, 45.
15.
Zurück zum Zitat Zhang, N., Feng, B., Ma, X., Sun, K., Xu, G., & Zhou, Y. (2019). Dapagliflozin improves left ventricular remodeling and aorta sympathetic tone in a pig model of heart failure with preserved ejection fraction. Cardiovascular Diabetology, 18(1), 107. Zhang, N., Feng, B., Ma, X., Sun, K., Xu, G., & Zhou, Y. (2019). Dapagliflozin improves left ventricular remodeling and aorta sympathetic tone in a pig model of heart failure with preserved ejection fraction. Cardiovascular Diabetology, 18(1), 107.
16.
Zurück zum Zitat Matboli, M., Shafei, A. E., Agwa, S. H. A., Elzahy, S. S., Anwar, A. K., Mansour, A. R., Gaber, A. I., Said, A. E. A., Lwis, P., & Hamdy, M. (2019). Identification of novel molecular network expression in acute myocardial infarction. Current Genomics, 20(5), 340–348.CrossRefPubMedPubMedCentral Matboli, M., Shafei, A. E., Agwa, S. H. A., Elzahy, S. S., Anwar, A. K., Mansour, A. R., Gaber, A. I., Said, A. E. A., Lwis, P., & Hamdy, M. (2019). Identification of novel molecular network expression in acute myocardial infarction. Current Genomics, 20(5), 340–348.CrossRefPubMedPubMedCentral
17.
Zurück zum Zitat Brooks, G. C., Lee, B. K., Rao, R., Lin, F., Morin, D. P., Zweibel, S. L., Buxton, A. E., Pletcher, M. J., Vittinghoff, E., & Olgin, J. E. (2016). Predicting persistent left ventricular dysfunction following myocardial infarction: The PREDICTS study. Journal of the American College of Cardiology, 67(10), 1186–1196.CrossRefPubMedPubMedCentral Brooks, G. C., Lee, B. K., Rao, R., Lin, F., Morin, D. P., Zweibel, S. L., Buxton, A. E., Pletcher, M. J., Vittinghoff, E., & Olgin, J. E. (2016). Predicting persistent left ventricular dysfunction following myocardial infarction: The PREDICTS study. Journal of the American College of Cardiology, 67(10), 1186–1196.CrossRefPubMedPubMedCentral
18.
Zurück zum Zitat Lahnwong, S., Palee, S., Apaijai, N., Sriwichaiin, S., Kerdphoo, S., Jaiwongkam, T., Chattipakorn, S. C., & Chattipakorn, N. (2020). Acute dapagliflozin administration exerts cardioprotective effects in rats with cardiac ischemia/reperfusion injury. Cardiovascular Diabetology, 19(1), 91. Lahnwong, S., Palee, S., Apaijai, N., Sriwichaiin, S., Kerdphoo, S., Jaiwongkam, T., Chattipakorn, S. C., & Chattipakorn, N. (2020). Acute dapagliflozin administration exerts cardioprotective effects in rats with cardiac ischemia/reperfusion injury. Cardiovascular Diabetology, 19(1), 91.
19.
Zurück zum Zitat Tanajak, P., Sa-Nguanmoo, P., Sivasinprasasn, S., Thummasorn, S., Siri-Angkul, N., Chattipakorn, S. C., & Chattipakorn, N. (2018). Cardioprotection of dapagliflozin and vildagliptin in rats with cardiac ischemia-reperfusion injury. Journal of Endocrinology, 236(2), 69–84. Tanajak, P., Sa-Nguanmoo, P., Sivasinprasasn, S., Thummasorn, S., Siri-Angkul, N., Chattipakorn, S. C., & Chattipakorn, N. (2018). Cardioprotection of dapagliflozin and vildagliptin in rats with cardiac ischemia-reperfusion injury. Journal of Endocrinology, 236(2), 69–84.
20.
Zurück zum Zitat von Lewinski, D., Benedikt, M., Tripolt, N., Wallner, M., Sourij, H., & Kolesnik, E. (2021). Can sodium-glucose cotransporter 2 inhibitors be beneficial in patients with acute myocardial infarction? Kardiologia Polska, 79(5), 503–509. von Lewinski, D., Benedikt, M., Tripolt, N., Wallner, M., Sourij, H., & Kolesnik, E. (2021). Can sodium-glucose cotransporter 2 inhibitors be beneficial in patients with acute myocardial infarction? Kardiologia Polska, 79(5), 503–509.
21.
Zurück zum Zitat Lee, T. M., Chang, N. C., & Lin, S. Z. (2017). Dapagliflozin, a selective SGLT2 Inhibitor, attenuated cardiac fibrosis by regulating the macrophage polarization via STAT3 signaling in infarcted rat hearts. Free Radical Biology & Medicine, 104, 298–310.CrossRefPubMed Lee, T. M., Chang, N. C., & Lin, S. Z. (2017). Dapagliflozin, a selective SGLT2 Inhibitor, attenuated cardiac fibrosis by regulating the macrophage polarization via STAT3 signaling in infarcted rat hearts. Free Radical Biology & Medicine, 104, 298–310.CrossRefPubMed
23.
Zurück zum Zitat Jiang, B., & Liao, R. (2010). The paradoxical role of inflammation in cardiac repair and regeneration. Journal of Cardiovascular Translational Research, 3(4), 410–416.CrossRefPubMed Jiang, B., & Liao, R. (2010). The paradoxical role of inflammation in cardiac repair and regeneration. Journal of Cardiovascular Translational Research, 3(4), 410–416.CrossRefPubMed
24.
Zurück zum Zitat Berezin, A. E., & Berezin, A. A. (2020). Adverse cardiac remodelling after acute myocardial infarction: Old and new biomarkers. Disease Markers, 2020, 1215802. Berezin, A. E., & Berezin, A. A. (2020). Adverse cardiac remodelling after acute myocardial infarction: Old and new biomarkers. Disease Markers, 2020, 1215802.
25.
Zurück zum Zitat Pascual-Figal, D. A., Bayes-Genis, A., Asensio-Lopez, M. C., Hernández-Vicente, A., Garrido-Bravo, I., Pastor-Perez, F., Díez, J., Ibáñez, B., & Lax, A. (2019). The interleukin-1 axis and risk of death in patients with acutely decompensated heart failure. Journal of the American College of Cardiology, 73(9), 1016–1025.CrossRefPubMed Pascual-Figal, D. A., Bayes-Genis, A., Asensio-Lopez, M. C., Hernández-Vicente, A., Garrido-Bravo, I., Pastor-Perez, F., Díez, J., Ibáñez, B., & Lax, A. (2019). The interleukin-1 axis and risk of death in patients with acutely decompensated heart failure. Journal of the American College of Cardiology, 73(9), 1016–1025.CrossRefPubMed
26.
Zurück zum Zitat Groot, H. E., Al Ali, L., van der Horst, I. C. C., Schurer, R. A. J., van der Werf, H. W., Lipsic, E., van Veldhuisen, D. J., Karper, J. C., & van der Harst, P. (2019). Plasma interleukin 6 levels are associated with cardiac function after ST-elevation myocardial infarction. Clinical Research in Cardiology, 108(6), 612–621.CrossRefPubMed Groot, H. E., Al Ali, L., van der Horst, I. C. C., Schurer, R. A. J., van der Werf, H. W., Lipsic, E., van Veldhuisen, D. J., Karper, J. C., & van der Harst, P. (2019). Plasma interleukin 6 levels are associated with cardiac function after ST-elevation myocardial infarction. Clinical Research in Cardiology, 108(6), 612–621.CrossRefPubMed
27.
Zurück zum Zitat Janczewski, A. M., Kadokami, T., Lemster, B., Frye, C. S., McTiernan, C. F., & Feldman, A. M. (2003). Morphological and functional changes in cardiac myocytes isolated from mice overexpressing TNF-alpha. American Journal of Physiology. Heart and Circulatory Physiology, 284(3), H960-969.CrossRefPubMed Janczewski, A. M., Kadokami, T., Lemster, B., Frye, C. S., McTiernan, C. F., & Feldman, A. M. (2003). Morphological and functional changes in cardiac myocytes isolated from mice overexpressing TNF-alpha. American Journal of Physiology. Heart and Circulatory Physiology, 284(3), H960-969.CrossRefPubMed
28.
Zurück zum Zitat Bryant, D., Becker, L., Richardson, J., Shelton, J., Franco, F., Peshock, R., Thompson, M., & Giroir, B. (1998). Cardiac failure in transgenic mice with myocardial expression of tumor necrosis factor-alpha. Circulation, 97(14), 1375–1381.CrossRefPubMed Bryant, D., Becker, L., Richardson, J., Shelton, J., Franco, F., Peshock, R., Thompson, M., & Giroir, B. (1998). Cardiac failure in transgenic mice with myocardial expression of tumor necrosis factor-alpha. Circulation, 97(14), 1375–1381.CrossRefPubMed
29.
Zurück zum Zitat Dobaczewski, M., Chen, W., & Frangogiannis, N. G. (2011). Transforming growth factor (TGF)-β signaling in cardiac remodeling. Journal of Molecular and Cellular Cardiology, 51(4), 600–606.CrossRefPubMed Dobaczewski, M., Chen, W., & Frangogiannis, N. G. (2011). Transforming growth factor (TGF)-β signaling in cardiac remodeling. Journal of Molecular and Cellular Cardiology, 51(4), 600–606.CrossRefPubMed
30.
Zurück zum Zitat Zhu, Y., Hu, C., Du, Y., Zhang, J., Liu, J., Han, H., & Zhao, Y. (2019). Significant association between admission serum monocyte chemoattractant protein-1 and early changes in myocardial function in patients with first ST-segment elevation myocardial infarction after primary percutaneous coronary intervention. BMC Cardiovascular Disorders, 19(1), 107. Zhu, Y., Hu, C., Du, Y., Zhang, J., Liu, J., Han, H., & Zhao, Y. (2019). Significant association between admission serum monocyte chemoattractant protein-1 and early changes in myocardial function in patients with first ST-segment elevation myocardial infarction after primary percutaneous coronary intervention. BMC Cardiovascular Disorders, 19(1), 107.
31.
Zurück zum Zitat Lino, D. O. C., Freitas, I. A., Meneses, G. C., Martins, A. M. C., Daher, E. F., Rocha, J. H. C., & Silva Junior, G. B. (2019). Interleukin-6 and adhesion molecules VCAM-1 and ICAM-1 as biomarkers of post-acute myocardial infarction heart failure. Braz J Med Biol Res, 52(12), e8658. Lino, D. O. C., Freitas, I. A., Meneses, G. C., Martins, A. M. C., Daher, E. F., Rocha, J. H. C., & Silva Junior, G. B. (2019). Interleukin-6 and adhesion molecules VCAM-1 and ICAM-1 as biomarkers of post-acute myocardial infarction heart failure. Braz J Med Biol Res, 52(12), e8658.
32.
Zurück zum Zitat Jose Corbalan, J., Vatner, D. E., & Vatner, S. F. (2016). Myocardial apoptosis in heart disease: Does the emperor have clothes? Basic Research in Cardiology, 111(3), 31. Jose Corbalan, J., Vatner, D. E., & Vatner, S. F. (2016). Myocardial apoptosis in heart disease: Does the emperor have clothes? Basic Research in Cardiology, 111(3), 31.
33.
Zurück zum Zitat Baldi, A., Abbate, A., Bussani, R., Patti, G., Melfi, R., Angelini, A., Dobrina, A., Rossiello, R., Silvestri, F., Baldi, F., & Di Sciascio, G. (2002). Apoptosis and post-infarction left ventricular remodeling. Journal of Molecular and Cellular Cardiology, 34(2), 165–174.CrossRefPubMed Baldi, A., Abbate, A., Bussani, R., Patti, G., Melfi, R., Angelini, A., Dobrina, A., Rossiello, R., Silvestri, F., Baldi, F., & Di Sciascio, G. (2002). Apoptosis and post-infarction left ventricular remodeling. Journal of Molecular and Cellular Cardiology, 34(2), 165–174.CrossRefPubMed
34.
Zurück zum Zitat Liu, F. Y., Fan, D., Yang, Z., Tang, N., Guo, Z., Ma, S. Q., Ma, Z. G., Wu, H. M., Deng, W., & Tang, Q. Z. (2019a). TLR9 is essential for HMGB1-mediated post-myocardial infarction tissue repair through affecting apoptosis, cardiac healing, and angiogenesis. Cell Death & Disease, 10(7), 480. Liu, F. Y., Fan, D., Yang, Z., Tang, N., Guo, Z., Ma, S. Q., Ma, Z. G., Wu, H. M., Deng, W., & Tang, Q. Z. (2019a). TLR9 is essential for HMGB1-mediated post-myocardial infarction tissue repair through affecting apoptosis, cardiac healing, and angiogenesis. Cell Death & Disease, 10(7), 480.
35.
Zurück zum Zitat Porta, C., Paglino, C., & Mosca, A. (2014). Targeting PI3K/Akt/mTOR signaling in cancer. Frontiers in Oncology, 4, 64. Porta, C., Paglino, C., & Mosca, A. (2014). Targeting PI3K/Akt/mTOR signaling in cancer. Frontiers in Oncology, 4, 64.
36.
Zurück zum Zitat Chen, L., Liu, P., Feng, X., & Ma, C. (2017). Salidroside suppressing LPS-induced myocardial injury by inhibiting ROS-mediated PI3K/Akt/mTOR pathway in vitro and in vivo. Journal of Cellular and Molecular Medicine, 21(12), 3178–3189. Chen, L., Liu, P., Feng, X., & Ma, C. (2017). Salidroside suppressing LPS-induced myocardial injury by inhibiting ROS-mediated PI3K/Akt/mTOR pathway in vitro and in vivo. Journal of Cellular and Molecular Medicine, 21(12), 3178–3189.
37.
Zurück zum Zitat Sun, X., Han, F., Lu, Q., Li, X., Ren, D., Zhang, J., Han, Y., Xiang, Y. K., & Li, J. (2020). Empagliflozin ameliorates obesity-related cardiac dysfunction by regulating Sestrin2-mediated AMPK-mTOR signaling and redox homeostasis in high-fat diet-induced obese mice. Diabetes, 69(6), 1292–1305. Sun, X., Han, F., Lu, Q., Li, X., Ren, D., Zhang, J., Han, Y., Xiang, Y. K., & Li, J. (2020). Empagliflozin ameliorates obesity-related cardiac dysfunction by regulating Sestrin2-mediated AMPK-mTOR signaling and redox homeostasis in high-fat diet-induced obese mice. Diabetes, 69(6), 1292–1305.
38.
Zurück zum Zitat Radlinger, B., Hornsteiner, F., Folie, S., Salvenmoser, W., Haubner, B. J., Schuetz, T., Haas, S., Ress, C., Adolph, T. E., Salzmann, K., Weiss, B., Tilg, H., & Kaser, S. (2020). Cardioprotective effects of short-term empagliflozin treatment in db/db mice. Science and Reports, 10(1), 19686. Radlinger, B., Hornsteiner, F., Folie, S., Salvenmoser, W., Haubner, B. J., Schuetz, T., Haas, S., Ress, C., Adolph, T. E., Salzmann, K., Weiss, B., Tilg, H., & Kaser, S. (2020). Cardioprotective effects of short-term empagliflozin treatment in db/db mice. Science and Reports, 10(1), 19686.
39.
Zurück zum Zitat Gong, L., Wang, X., Pan, J., Zhang, M., Liu, D., Liu, M., Li, L., & An, F. (2021). The co-treatment of rosuvastatin with dapagliflozin synergistically inhibited apoptosis via activating the PI3K/AKt/mTOR signaling pathway in myocardial ischemia/reperfusion injury rats. Open Med (Wars), 15(1), 47–57. Gong, L., Wang, X., Pan, J., Zhang, M., Liu, D., Liu, M., Li, L., & An, F. (2021). The co-treatment of rosuvastatin with dapagliflozin synergistically inhibited apoptosis via activating the PI3K/AKt/mTOR signaling pathway in myocardial ischemia/reperfusion injury rats. Open Med (Wars), 15(1), 47–57.
40.
Zurück zum Zitat Liu, Y., Wu, M., Xu, J., Xu, B., & Kang, L. (2021). Empagliflozin prevents from early cardiac injury post myocardial infarction in non-diabetic mice. Eur J Pharm Sci, 161, 105788. Liu, Y., Wu, M., Xu, J., Xu, B., & Kang, L. (2021). Empagliflozin prevents from early cardiac injury post myocardial infarction in non-diabetic mice. Eur J Pharm Sci, 161, 105788.
41.
Zurück zum Zitat Chen, H., Tran, D., Yang, H. C., Nylander, S., Birnbaum, Y., & Ye, Y. (2020). Dapagliflozin and Ticagrelor have additive effects on the attenuation of the activation of the NLRP3 inflammasome and the progression of diabetic cardiomyopathy: An AMPK-mTOR Interplay. Cardiovascular Drugs and Therapy, 34(4), 443–461. Chen, H., Tran, D., Yang, H. C., Nylander, S., Birnbaum, Y., & Ye, Y. (2020). Dapagliflozin and Ticagrelor have additive effects on the attenuation of the activation of the NLRP3 inflammasome and the progression of diabetic cardiomyopathy: An AMPK-mTOR Interplay. Cardiovascular Drugs and Therapy, 34(4), 443–461.
42.
Zurück zum Zitat LambersHeerspink, H. J., de Zeeuw, D., Wie, L., Leslie, B., & List, J. (2013). Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes. Diabetes, Obesity & Metabolism, 15(9), 853–862. LambersHeerspink, H. J., de Zeeuw, D., Wie, L., Leslie, B., & List, J. (2013). Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes. Diabetes, Obesity & Metabolism, 15(9), 853–862.
Metadaten
Titel
Dapagliflozin Improves Cardiac Function, Remodeling, Myocardial Apoptosis, and Inflammatory Cytokines in Mice with Myocardial Infarction
verfasst von
Kai Wang
Zhongming Li
Yan Sun
Xianling Liu
Wenjie Ma
Yinzhang Ding
Jian Hong
Lijun Qian
Di Xu
Publikationsdatum
02.12.2021
Verlag
Springer US
Erschienen in
Journal of Cardiovascular Translational Research / Ausgabe 4/2022
Print ISSN: 1937-5387
Elektronische ISSN: 1937-5395
DOI
https://doi.org/10.1007/s12265-021-10192-y

Kompaktes Leitlinien-Wissen Innere Medizin (Link öffnet in neuem Fenster)

Mit medbee Pocketcards schnell und sicher entscheiden.
Leitlinien-Wissen kostenlos und immer griffbereit auf ihrem Desktop, Handy oder Tablet.

Neu im Fachgebiet Kardiologie

Vorhofflimmern: Antikoagulation vor Schlaganfall von Vorteil

Erleiden Menschen mit Vorhofflimmern einen ischämischen Schlaganfall, ist dieser weniger schwer, auch sind Infarktgröße und Blutungsrisiko geringer, wenn sie zuvor orale Antikoagulanzien erhalten haben. Die Art der Antikoagulation spielt dabei keine Rolle.

Mehr Cholesterin im Essen = höheres Herzinfarktrisiko

Je mehr Cholesterin man täglich über die Nahrung zu sich nimmt, desto höher ist offenbar das Herzinfarktrisiko – das legt eine Studie mit US-Veteranen zumindest für Männer nahe.

Antikoagulation bei Vorhofflimmern: Sind DOAK noch zu toppen?

Gegen Thromboembolien so wirksam wie ein DOAK, bei zugleich geringerem Blutungsrisiko – werden Faktor-XI-Hemmer als neue Antikoagulanzien dieser Erwartung gerecht? Eine aktuell publizierte Vergleichsstudie gibt darüber Aufschluss.

"Stammzell-Pflaster" gegen geschwächte Herzen: Hoffnung oder Hype?

Eine Nature-Publikation zur Behandlung der Herzinsuffizienz mit von Stammzellen abgeleiteten Herzzellen sorgt in Publikumsmedien für Wirbel. Deren Erkenntnisse sind in der Tat spektakulär – und gleichzeitig vorläufig und ernüchternd. 

EKG Essentials: EKG befunden mit System (Link öffnet in neuem Fenster)

In diesem CME-Kurs können Sie Ihr Wissen zur EKG-Befundung anhand von zwölf Video-Tutorials auffrischen und 10 CME-Punkte sammeln.
Praxisnah, relevant und mit vielen Tipps & Tricks vom Profi.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.